Rioprostil, a new prostaglandin E1, prevents cyclosporin A-induced damage to endocrine and exocrine pancreas.
The possibility that rioprostil can prevent cyclosporin A-induced damage to the pancreas is investigated. Cyclosporin A is given to rats once daily intragastrically in doses of 5, 10 and 20 mg/kg body weight. These doses cause dose dependent significant reduction of insulin release and enzyme secretion from the arterially perfused isolated pancreas. The subcutaneous injection of rioprostil, 15 micrograms/kg twice daily, could completely prevent the effects of 5 mg/kg cyclosporin A on insulin release and could completely prevent the effects of 5 mg/kg cyclosporin A on insulin release and could completely prevent the effects of 5 mg/kg cyclosporin A on insulin release and could also afford significant protection from the effects of 10 and 20 mg/kg cyclosporin A on both insulin release and enzyme secretion. The cytoprotective action of rioprostil on the pancreas may have therapeutic implications.
Müller
M
M
Department of Medicine, University of Essen, FRG.
Degenhardt
H
H
Bergmann
K
K
Coone
H
H
Löhr
M
M
Klöppel
G
G
Goebell
H
H
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003524:Cyclosporins / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D011458:Prostaglandins E / Q000494:pharmacology*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D016630:Rioprostil
D000897:Anti-Ulcer Agents; D003524:Cyclosporins; D007328:Insulin; D011458:Prostaglandins E; D011465:Prostaglandins, Synthetic; D016630:Rioprostil